NASDAQ:KYTH

(KYTH) (KYTH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.09
$0.09
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KYTH stock logo

About (KYTH) Stock (NASDAQ:KYTH)

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

KYTH Stock News Headlines

Investors Alert: The Next Big Thing in Weight Loss
UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.
Agro Capital Management Corp ACMB
Xponential Fitness to acquire Lindora
Investors Alert: The Next Big Thing in Weight Loss
UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.
RCI Hospitality declares $0.06 dividend
eXp World Holdings Inc 44Y
PBA draft a rich harvest
Animals dream too—here's what we know
See More Headlines
Receive KYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KYTH) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2015
Today
5/04/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KYTH
CUSIP
50157010
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

KYTH Stock Analysis - Frequently Asked Questions

How were (KYTH)'s earnings last quarter?

(KYTH) (NASDAQ:KYTH) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter.

What other stocks do shareholders of (KYTH) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (KYTH) investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), (RPTP) (RPTP), Altaba (AABA), Intercept Pharmaceuticals (ICPT), Incyte (INCY), NPS Pharmaceuticals (NPSP), OPKO Health (OPK) and Puma Biotechnology (PBYI).

This page (NASDAQ:KYTH) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners